Table 4 Absolute decline in DLCO from baseline over 12 months
Placebo group | Cyclophosphamide group | |||||
|---|---|---|---|---|---|---|
Number of subjects | Absolute decline in DLCO from baseline (%), mean (SD) | p Value | Number of subjects | Absolute decline in DLCO from baseline (%), mean (SD) | p Value | |
Visual maximum fibrosis score | ||||||
0–25 % | 19 | −1.6 (10.8) | 0.62 | 13 | −6.0 (9.2) | 0.64 |
26–100 % | 29 | −3.2 (10.9) | 30 | −4.7 (7.2) | ||
Goh and Wells criteria, unadjusted stratification | ||||||
<20 % | 22 | −3.0 (11.5) | 0.98 | 15 | −6.9 (8.4) | 0.30 |
>20 % | 25 | −3.0 (9.9) | 30 | −4.3 (7.1) | ||
Goh and Wells criteria with indeterminate results on HRCT (10–30 %), adjusted stratification | ||||||
Minimal disease | 8 | −1.65 (11.5) | 0.84 | 12 | −1.3 (7.9) | 0.04 |
Extensive disease | 39 | −2.5 (10.8) | 32 | −6.9 (6.9) | ||
QILD WL | ||||||
<20 % | 10 | 4.8 (8.6) | 0.01 | 5 | −7.6 (10.2) | 0.58 |
>20 % | 37 | −4.3 (10.6) | 38 | −4.7 (7.4) | ||
QILD ZM | ||||||
<25 % | 2 | 12.7 (3.2) | 0.02 | 2 | −13.7 (3.0) | 0.08 |
>25 % | 45 | −3.0 (10.5) | 41 | −4.7 (7.7) | ||
QLF WL | ||||||
<20 % | 42 | −1.9 (10.4) | 0.63 | 39 | −5.5 (7.9) | 0.08 |
>20 % | 5 | −5.9 (14.9) | 4 | −1.4 (3.2) | ||
QLF ZM | ||||||
<25 % | 21 | 0.3 (12.3) | 0.15 | 20 | −6.0 (8.1) | 0.46 |
>25 % | 26 | −4.5 (9.1) | 23 | −4.2 (7.5) | ||